These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24974457)

  • 1. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
    Lu Y; Qiao F; You XF; Yang XY
    Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Mycobacterium tuberculosis cytochromes P450: physiology, biochemistry & molecular intervention.
    McLean KJ; Belcher J; Driscoll MD; Fernandez CC; Le Van D; Bui S; Golovanova M; Munro AW
    Future Med Chem; 2010 Aug; 2(8):1339-53. PubMed ID: 21426022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
    Ortiz de Montellano PR
    J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes.
    McLean KJ; Marshall KR; Richmond A; Hunter IS; Fowler K; Kieser T; Gurcha SS; Besra GS; Munro AW
    Microbiology (Reading); 2002 Oct; 148(Pt 10):2937-2949. PubMed ID: 12368427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?
    Ortega Ugalde S; Boot M; Commandeur JNM; Jennings P; Bitter W; Vos JC
    Appl Microbiol Biotechnol; 2019 May; 103(9):3597-3614. PubMed ID: 30810776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis.
    Ortega Ugalde S; Wallraven K; Speer A; Bitter W; Grossmann TN; Commandeur JNM
    Biochem Pharmacol; 2020 Jul; 177():113938. PubMed ID: 32224137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis.
    Munro AW; McLean KJ; Marshall KR; Warman AJ; Lewis G; Roitel O; Sutcliffe MJ; Kemp CA; Modi S; Scrutton NS; Leys D
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):625-30. PubMed ID: 12773169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems.
    McLean KJ; Dunford AJ; Neeli R; Driscoll MD; Munro AW
    Arch Biochem Biophys; 2007 Aug; 464(2):228-40. PubMed ID: 17482138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
    McLean KJ; Munro AW
    Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel cYY analogues targeting Mycobacterium tuberculosis CYP121A1.
    Kishk SM; McLean KJ; Sood S; Helal MA; Gomaa MS; Salama I; Mostafa SM; de Carvalho LPS; Munro AW; Simons C
    Bioorg Med Chem; 2019 Apr; 27(8):1546-1561. PubMed ID: 30837169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Function Analysis of the Essential
    Padayachee T; Lamb DC; Nelson DR; Syed K
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors.
    Walter I; Adam S; Gentilini MV; Kany AM; Brengel C; Thomann A; Sparwasser T; Köhnke J; Hartmann RW
    ChemMedChem; 2021 Sep; 16(18):2786-2801. PubMed ID: 34010508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Characterization and Ligand/Inhibitor Identification Provide Functional Insights into the Mycobacterium tuberculosis Cytochrome P450 CYP126A1.
    Chenge JT; Duyet LV; Swami S; McLean KJ; Kavanagh ME; Coyne AG; Rigby SE; Cheesman MR; Girvan HM; Levy CW; Rupp B; von Kries JP; Abell C; Leys D; Munro AW
    J Biol Chem; 2017 Jan; 292(4):1310-1329. PubMed ID: 27932461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.
    McLean KJ; Carroll P; Lewis DG; Dunford AJ; Seward HE; Neeli R; Cheesman MR; Marsollier L; Douglas P; Smith WE; Rosenkrands I; Cole ST; Leys D; Parish T; Munro AW
    J Biol Chem; 2008 Nov; 283(48):33406-16. PubMed ID: 18818197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.
    Guardiola-Diaz HM; Foster LA; Mushrush D; Vaz AD
    Biochem Pharmacol; 2001 Jun; 61(12):1463-70. PubMed ID: 11377375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Mycobacterium tuberculosis transpeptidase Ldt
    de Munnik M; Lohans CT; Lang PA; Langley GW; Malla TR; Tumber A; Schofield CJ; Brem J
    Chem Commun (Camb); 2019 Aug; 55(69):10214-10217. PubMed ID: 31380528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450.
    Bukhdruker S; Varaksa T; Grabovec I; Marin E; Shabunya P; Kadukova M; Grudinin S; Kavaleuski A; Gusach A; Gilep A; Borshchevskiy V; Strushkevich N
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.